For the quarter ended June 2024, Adaptive Biotechnologies (ADPT) reported revenue of $43.19 million, down 11.7% over the same period last year. EPS came in at -$0.26, compared to -$0.33 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $38.52 million, representing a surprise of +12.13%. The company delivered an EPS surprise of +18.75%, with the consensus EPS estimate being -$0.32. While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this lifesciences research company would post a loss of $0.35 per share when it actually produced a loss of $0.33, delivering a surprise of 5.71%. Over the last four qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 ...

EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. "We had another strong quarter with MRD revenue growth of 36% and deliver ...

SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024. “We had another strong quarter with MRD revenue growth of 36% and delivered significant reductions in operating spend and cash burn versus prior year,” said ...

Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant. That is, humans will always try to find treatment solutions for various conditions and diseases. Second, the underlying sector will likely be a massive one based on expert projections. According to Precedence Research, the precision medicine market size reached a valuation of $73.49 billion in 2022. By 2030, the sector i ...

SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live ...

SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in several oral and poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting taking pla ...

SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in several oral and poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting taking pl ...

To be completely upfront, small-cap stocks to buy are risky. They’re the equivalent of plus-money bets or plus odds. Let me explain.In the world of sports gambling, you have the option of either wagering on the favorite or the underdog. Favorites are that way for a reason. Still, underdogs can occasionally spark an upset. And these bets can yield exponentially large rewards. You just have to know when to place the bets and for whom.That’s always going to be a tricky endeavor. However, if you’re willing to r ...